CMPS COMPASS Pathways plc
USHealthcareAs of 2026-07-09 16:00
Why CMPS matters now
COMPASS Pathways plc (CMPS) is a US stock in Healthcare. The latest InvestLog snapshot shows $13.60 with -2.61% on the session and $1.31B in market capitalization; recent performance reads 1-month +24.43% and YTD +81.59%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $91.0M, and EPS of $-0.30. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -13.2%.
The latest indexable market news headline is "Compass Pathways: 'Strong Buy' COMP360 Trial Wins And Q4 NDA Full Submission" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $18.00; recent insider activity includes Tregoning Kathleen filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.22
P/S
0.00
EV/EBITDA
-4.19
DCF Value
$1.38
FCF Yield
-13.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-151.0%
ROA
-33.7%
ROIC
-44.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $91.0M | $-0.30 |
| Q4 2025 | $0.00 | $-93.9M | $-1.00 |
| FY 2025 | $0.00 | $-287.9M | $-3.08 |
| Q3 2025 | $0.00 | $-137.7M | $-1.44 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$18.57
Target (Median)
$18.00
Target Range
$15.00 - $22.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Care Facilities
Country
GB
Exchange
—
Beta
2.51
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.